Beneficial effect of Raloxifene on high turn-over bone in chronic hemodialysis patients
- Conditions
- chronic kidney disease postmenopausal osteoporosis
- Registration Number
- JPRN-UMIN000001911
- Lead Sponsor
- Blood Purification Center, Osaka College of Medicine
- Brief Summary
Both the BAP and the TACP-5b levels were significantly decreased at week 4. The serum calcium value decreased consistently after the start of raloxifene therapy. The intact parathyroid hormone (iPTH) levels were likely increased at week 4. The ratio of BAP to iPTH levels and the ratio of TRACP-5b to iPTH levels both showed significant decreases over time. During the raloxifene therapy, no thrombosis or other drug-related adverse events developed.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 50
Not provided
1. Patients prescribed with bisphosphonate, aluminium, lanthanum, cinacalcet. 2. Patients with venous thrombosis or its history. 3. Immobilised patients in long term. 4. Patients with anti-phospholipid antibody syndrome. 5. Patients in pregnancy (including its possibility) and lactation. 6. Patinets with history of allergy to Raloxifene. 7. Patients with liver dysfunction.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method serum bone alkaline phosphatase (BAP) level serum bone-specific tartrate-resistant acid phosphatase (TRAP5b) level
- Secondary Outcome Measures
Name Time Method serum levels od iPTH, calcium, phosphate, total cholesterol, and triacylglyceride